ReviewNanomaterials (Basel, Switzerland)2020
Nanopharmaceutics: Part II-Production Scales and Clinically Compliant Production Methods.
Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fruit Wastes as a Valuable Source of Value-Added Compounds: A Collaborative Perspective.Molecules (Basel, Switzerland) · 2021Pooled it
- The Translational Paradox of Cancer Nanomedicine: Biological, Pharmacokinetic, and Manufacturing Barriers to Clinical Success.Biology · 2026Review
- Review
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Green Synthesis of Molecularly Imprinted Polymers: Advances Toward Sustainable Materials.Polymers · 2026Review
- SmartLipids in Drug Delivery: Redefining the Third Generation of Lipid Nanocarriers for Clinical and Industrial Translation.International journal of nanomedicine · 2026Review
- Advances in Biomimetic Cell Membrane Nanoplatforms for Renal-Targeted Theranostics: From Pathophysiological Basis to Membrane-Stratified Design.International journal of nanomedicine · 2026Review
- Lost in translation: the lack of agreement between surgeons and scientists regarding biomaterials research and innovation for treating bone defects.BMC medicine · 2024Article
- Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol.International journal of molecular sciences · 2022Review
- Multifunctional PLA/Gelatin Bionanocomposites for Tailored Drug Delivery Systems.Pharmaceutics · 2022Article
- Nanoformulation of Polyphenol Curcumin Enhances Cisplatin-Induced Apoptosis in Drug-Resistant MDA-MB-231 Breast Cancer Cells.Molecules (Basel, Switzerland) · 2022Article
- A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.International journal of molecular sciences · 2022Review
- The Honey BeeBiology · 2022Review
- Enhancement of Vancomycin Potential against Pathogenic Bacterial Strains via Gold Nano-Formulations: A Nano-Antibiotic Approach.Materials (Basel, Switzerland) · 2022Article
- Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence.Frontiers in digital health · 2022Review
- Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review.Current drug metabolism · 2022Review
- Hydroxyurea-loaded FeNaunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Bee Products: A Representation of Biodiversity, Sustainability, and Health.Life (Basel, Switzerland) · 2021Article
- Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye Disease.Pharmaceutics · 2021Article
- Hyaluronic Acid-Based Nanocapsules as Efficient Delivery Systems of Garlic Oil Active Components with Anticancer Activity.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations-nanopharmaceutics-have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing "Nanopharmaceutics: Part I-Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU" has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.